Geron (GERN) Other financing activities (2019 - 2026)
Geron (GERN) posted Other financing activities of $914000.0 for Q1 2026, up 165.8% sequentially from -$1.4 million in Q4 2025.
Geron (GERN) Other financing activities (2019 - 2026) Analysis & Trends
Geron has reported Other financing activities for 8 years, with the latest figure at $914000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $914000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $914000.0 (down 99.27% YoY) and the FY2024 annual result came in at $125.0 million, up 856.24% from the prior year.
- Other financing activities improved to $914000.0 in Q1 2026 per GERN's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Other financing activities peaked at $124.6 million in Q4 2024 and troughed at -$92.8 million in Q4 2023.
- A 5-year average of $10.2 million and a median of $694500.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2025: Other financing activities sank 41732.29% in 2023, then jumped 22125.0% in 2025.
- Over 5 years, Other financing activities stood at $223000.0 in 2022, then tumbled by 41732.29% to -$92.8 million in 2023, then soared by 234.25% to $124.6 million in 2024, then slumped by 101.11% to -$1.4 million in 2025, then soared by 165.8% to $914000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $914000.0, -$1.4 million, and $889000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 473,000.00 |
| Jun 30, 2026 | 473,000.00 |
| Mar 31, 2026 | 914,000.00 |
| Mar 31, 2026 | 914,000.00 |
| Dec 31, 2025 | -1.39 Mn |
| Dec 31, 2025 | -1.39 Mn |
| Sep 30, 2025 | 889,000.00 |
| Sep 30, 2025 | 889,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Dec 31, 2024 | 124.63 Mn |
| Dec 31, 2024 | 124.63 Mn |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 365,000.00 |
| Jun 30, 2024 | 365,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | -92.84 Mn |
| Dec 31, 2023 | -92.84 Mn |